In the adenocarcinomas tested by Yao et al., GPC3 expression was observed in 47 of 106 (44%) pancreatic adenocarcinoma tumor samples tested, and CK19 expression was observed in 63 of 106 (59%) pancreatic adenocarcinomas. This evidence concerns the gene GPC3 and pancreatic adenocarcinoma.